Charles River Labs Shows Strong Recovery | Business and Finance News

Charles River Laboratories is turning things around—posting strong Q2 results with a four-year high in Discovery and Safety Assessment bookings, organic revenue growth for the first time in a year, and beating earnings forecasts. Strategic asset sales are boosting margins, while manufacturing operations show improved efficiency. Management credits renewed biotech funding and more proposals for the rebound, though academic and government spending remains sluggish. They’re also navigating competitive pressures from Chinese labs by focusing on service quality and supply chain strength, while cautioning against reading one quarter’s margin as permanent. The company is eyeing early-stage research as a growth engine and is investing in digital pathology and bioanalysis. The big question? Will sustained funding for smaller biotechs keep driving demand—and can they turn new bookings into real revenue? Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/7b5a09f8c6c58429